Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1
Information source: Massachusetts General Hospital
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Neurofibromatosis Type 1; Cutaneous Neurofibromas
Intervention: Imiquimod 5% Cream (Drug)
Phase: N/A
Status: Active, not recruiting
Sponsored by: Massachusetts General Hospital Official(s) and/or principal investigator(s): Scott R. Plotkin, MD, PhD, Principal Investigator, Affiliation: Massachusetts General Hospital
Summary
The purpose of this study is to determine if imiquimod cream can reverse the growth of
neurofibromas. Imiquimod is a skin cream that works by stimulating the body's immune system
to respond to tumors. Imiquimod cream is approved for use in patients with various skin
lesions, including actinic keratosis, superficial basal cell carcinoma, and external genital
warts. Information from these studies, as well as previous laboratory studies, suggest that
imiquimod cream may help shrink neurofibromas or keep them from growing.
Clinical Details
Official title: Pilot Study of Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: To determine the effect of topical imiquimod 5% cream on tumor volume of cutaneous neurofibromas in adult subjects with neurofibromatosis 1
Secondary outcome: To correlate the inflammatory infiltrate adjacent to treated lesions during treatment with tumor response and to determine the number of circulating Tregs in this patient population
Detailed description:
- Three of the participant's tumors will be treated with imiquimod cream and one tumor
(out of all the remaining tumors) will be followed without treatment (control tumor).
- Participants will be given a tube of imiquimod cream and be asked to apply it to the
three tumors 5 times per week, for a full 6 weeks (Monday through Friday).
- Participants will be required to come to the hospital for examinations on Week 1, 2, 4
and 6 (+/- 3 calendar days) and after their last dose of imiquimod cream on Weeks 9, 12
and 18 (+/- 5 calendar days. The following tests and procedures will be performed: skin
test; vital signs and measurements and photographs of the tumors. Participants will be
asked to participate in an optional skin biopsy on Week 4 and research blood tests wil
lbe taken on Day 1.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients must have a diagnosis of NF1 based on NIH criterial with two or more of the
following characteristics:
- six or more cafe-au-lait macules (1. 5cm or greater in size)
- skin fold freckling in the axilla or groin
- optic pathway glioma
- two or more Lisch nodules of the iris
- distinctive bony lesions such as dysplasia of the sphenoid wing or of a long
bone such as the tibia
- two or more neurofibromas of any type of 1 or more plexiform neurofibroma
- first degree relative with NF1
- Participants must have at least four cutaneous neurofibromas on skin exam with the
following qualities:
- the lesion must be discrete by clinical exam and must not be contact with
another skin tumor
- the lesion must be amenable to measurement with calipers with minimum dimension
of 5mm and maximum dimension of 30mm
- the lesions must be located on the trunk, neck, or extremities (excluding the
hands and feet) and must be located in an area that can be photographed
- histologic confirmation of tumor type is not required in the setting of
compatible clinical setting
- No treatment with an investigation agent for cutaneous neurofibromas within the last
3 months
- 18 years of age or older
Exclusion Criteria:
- Pregnant and nursing women
- Patients who have had chemotherapy or radiotherapy within 6 weeks prior to entering
the study or those who have not recovered from adverse events due to agents
administered more than 6 weeks earlier
- Patients may not be receiving any other investigational agents
- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to imiquimod
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.
Locations and Contacts
Massachusetts General Hospital, Boston, Massachusetts 02114, United States
Additional Information
Starting date: March 2009
Last updated: March 4, 2013
|